| First Author | Warner K | Year | 2022 |
| Journal | Front Immunol | Volume | 13 |
| Pages | 948358 | PubMed ID | 36032129 |
| Mgi Jnum | J:327871 | Mgi Id | MGI:7333743 |
| Doi | 10.3389/fimmu.2022.948358 | Citation | Warner K, et al. (2022) Innate lymphoid cells in early tumor development. Front Immunol 13:948358 |
| abstractText | Innate and adaptive immune cells monitor, recognize, and eliminate transformed cells. Innate lymphoid cells (ILCs) are innate counterparts of T cells that play a key role in many facets of the immune response and have a profound impact on disease states, including cancer. ILCs regulate immune responses by responding and integrating a wide range of signals within the local microenvironment. As primarily tissue-resident cells, ILCs are ideally suited to sense malignant transformation and initiate anti-tumor immunity. However, as ILCs have been associated with anti-tumor and pro-tumor activities in established tumors, they could potentially have dual functions during carcinogenesis by promoting or suppressing the malignant outgrowth of premalignant lesions. Here we discuss emerging evidence that shows that ILCs can impact early tumor development by regulating immune responses against transformed cells, as well as the environmental cues that potentially induce ILC activation in premalignant lesions. |
